BXQ-350: A phase 1b/2 placebo controlled, double blinded study on the efficacy and safety of BXQ-350 in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal carcinoma (mCRC).

Authors

Reema Anil Patel, University of Kentucky
Ari David Baron, Sutter/California Pacific Medical Center
Brian C. Boulmay, LSU Health Sciences Center - New OrleansFollow
Daniel Blake Flora, St Elizabeth Medical Center
Julie Anne L Gemmill, Stony Brook University Hospital
Fa Chyi Lee, University of California
Davendra Sohal, University of Cincinnati Cancer Center
Grant Richard Williams, University of Alabama at Birmingham
Richard Charles Curry, CTI Clinical Trial and Consulting
Michael Gazda, Bexion Pharmaceuticals
Joseph D. Purvis, Purvis Oncology
Gilles Tapolsky, Bexion Pharmaceuticals
Ray Takigiku, Bexion Pharmaceuticals

Document Type

Conference Proceeding

Publication Date

1-22-2024

Publication Title

Journal of Clinical Oncology

Abstract

2024 ASCO Gastrointestinal Cancers Symposium, January 18 - 20, 2024, San Francisco, CA

Volume

42

Issue

3 Supplement

Comments

Abstract TPS224

Recommended Citation

Patel, Reema Anil; Baron, Ari David; Boulmay, Brian C.; Flora, Daniel Blake; Gemmill, Julie Anne L; Lee, Fa Chyi; Sohal, Davendra; Williams, Grant Richard; Curry, Richard Charles; Gazda, Michael; Purvis, Joseph D.; Tapolsky, Gilles; and Takigiku, Ray, "BXQ-350: A phase 1b/2 placebo controlled, double blinded study on the efficacy and safety of BXQ-350 in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal carcinoma (mCRC)." (2024). School of Medicine Faculty Publications. 2612.
https://digitalscholar.lsuhsc.edu/som_facpubs/2612
10.1200/JCO.2024.42.3_suppl.TPS224